Zobrazeno 1 - 10
of 295
pro vyhledávání: '"Hans Wadenvik"'
Publikováno v:
Haematologica, Vol 93, Iss 7 (2008)
Externí odkaz:
https://doaj.org/article/798f60efc12f41669184992670e41cef
Autor:
Torsten Dahlén, Gustaf Edgren, Per Ljungman, Hjalmar Flygt, Johan Richter, Ulla Olsson‐Strömberg, Hans Wadenvik, Arta Dreimane, Kristina Myhr‐Eriksson, Jingcheng Zhao, Anders Själander, Martin Höglund, Leif Stenke
Tyrosine kinase inhibitors (TKIs) have profoundly improved the clinical outcome for patients with chronic myeloid leukemia (CML), but their overall survival is still subnormal and the treatment is associated with adverse events. In a large cohort-stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::000471abf890d56df7d88a079b9b3d4e
http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-191878
http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-191878
Autor:
Leif Stenke, Berit Markevärn, Lovisa Wennström, Arta Dremaine, Fredrik Sandin, Anna Lübking, Torsten Dahlén, Ulla Olsson-Strömberg, Stina Söderlund, Hans Wadenvik, Johan Richter, Anders Själander, Hjalmar Flygt, Karin Olsson, Kristina Myhr-Eriksson, Martin Höglund
Clinical trials show that tyrosine kinase inhibitor (TKI) treatment can be discontinued in selected patients with chronic myeloid leukaemia (CML). Although updated CML guidelines support such procedure in clinical routine, data on TKI stopping outsid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a264901d039663478ac09b63ce0e08aa
http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-182096
http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-182096
Autor:
Satu Mustjoki, Helena Ågerstam, Carl Högberg, Carl Sandén, Hans Wadenvik, Thoas Fioretos, Henrik Lilljebjörn, Niklas Landberg, Kristian Reckzeh, Johan Richter, Marcus Järås, Marianne Rissler, Nils Hansen, Sofia von Palffy, Christine Karlsson, Maria Askmyr, Kimmo Porkka
Publikováno v:
Blood. 128:2683-2693
Chronic myeloid leukemia (CML) is currently treated with tyrosine kinase inhibitors, but these do not effectively eliminate the CML stem cells. As a consequence, CML stem cells persist and cause relapse in most patients upon drug discontinuation. Fur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c9512b0498b7103a3bd541edd0ffa17
https://doi.org/10.1182/blood-2015-11-679985
https://doi.org/10.1182/blood-2015-11-679985
Autor:
Marieke Schoonen, Georg Kreuzbauer, Hans Wadenvik, Michael Steurer, Philippe Quittet, Dominik Selleslag, Jean-François Viallard, Tomas Kozak, Ann Janssens, Helen A. Papadaki, Georgia Kaiafa, Laura Belton
Publikováno v:
European Journal of Haematology. 98:112-120
Objective Romiplostim has maintained long-term platelet counts in patients with immune thrombocytopenia (ITP) for up to 5 years in clinical studies. This prospective observational study aimed to describe romiplostim utilisation and outcomes in Europe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df3d4c72a64b0214676b682176f49e1c
https://doi.org/10.1111/ejh.12807
https://doi.org/10.1111/ejh.12807
Autor:
Fredrik Sandin, Ulla Olsson-Strömberg, Leif Stenke, Anna Lübking, Arta Dreimane, Torsten Dahlén, Maria Creignou, Johan Richter, Anders Själander, Martin Höglund, Hans Wadenvik, Berit Markevärn, Stina Söderlund
Publikováno v:
European Journal of Haematology. 98:57-66
The primary goal in management of chronic phase (CP) chronic myeloid leukaemia (CML) is to prevent disease progression to accelerated phase (AP) or blast crisis (BC). We have evaluated progression rates in a decentralised healthcare setting and chara
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc913344d95ef3079fb0857772a0b3ef
https://doi.org/10.1111/ejh.12785
https://doi.org/10.1111/ejh.12785
Autor:
Ulla Olsson-Strömberg, Fredrik Sandin, Niklas Gunnarsson, Mats Lambe, Hans Wadenvik, Magnus Björkholm, Arta Dreimane, Solveig Wållberg Jonsson, Leif Stenke, Anders Själander, Martin Höglund, Johan Richter, Berit Markevärn
Publikováno v:
Leukemia. 30:1562-1567
Background: In a recent, large population-based study we identified an increased risk of a second malignancy in patients following a diagnosis of Chronic Myeloid Leukemia (CML), as compared to an age- and gender-matched control cohort (Gunnarsson et
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b4ad2bc19f0dc01b46a766cc69acca8
https://doi.org/10.1038/leu.2016.59
https://doi.org/10.1038/leu.2016.59
Autor:
Leif Stenke, Arta Dreimane, Anders Själander, Niklas Gunnarsson, Magnus Björkholm, Fredrik Sandin, Hans Wadenvik, Mats Lambe, Martin Höglund, Johan Richter, Ulla Olsson-Strömberg, Berit Markevärn
No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia : a population-based study in Sweden
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::449af1f928980cbc1650aeb450421432
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-139911
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-139911
Differences in gene expression and cytokine levels between newly diagnosed and chronic pediatric ITP
Autor:
Ming Hou, Intawat Nookaew, Hans Wadenvik, Yu Hou, Frida Strömberg Célind, Qian Wang, Linlin Shao, Xiuli Ju, Margareta Jernås, Bob Olsson, Karin Mellgren
Publikováno v:
Blood. 122:1789-1792
Immune thrombocytopenia (ITP) is an autoimmune disease where platelets are destroyed prematurely. In the majority of children the disease resolves, but in some it becomes chronic. To investigate whether these 2 phases of the disease are molecularly s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aeda02d418a8a92279dfb39fa42f7d7c
https://doi.org/10.1182/blood-2013-05-502807
https://doi.org/10.1182/blood-2013-05-502807
Autor:
Tomas Olsson, Kaj Blennow, Alan Gillett, Clas Malmeström, Margareta Jernås, Bob Olsson, Hans Wadenvik, Lars Alfredsson, Niklas Mattsson, Henrik Zetterberg, Mohsen Khademi, Markus Axelsson, Jan Lycke, Ingrid Kockum
Publikováno v:
Multiple Sclerosis Journal. 19:871-876
Background: Recently, a polymorphism in the LIGHT gene was shown to increase the risk of multiple sclerosis (MS) in a genome-wide association study (GWAS). Objective: Our aim was to investigate if serum levels of LIGHT were affected by this polymorph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91e17384d992462bc5b34aafcb8d7878
https://doi.org/10.1177/1352458512463766
https://doi.org/10.1177/1352458512463766